Get the Stockscreener App
6.60
0.15%
0.010
After Hours:
6.71
0.11
+1.67%
Plus Therapeutics Inc stock is traded at $6.60, with a volume of 102.46K.
It is up +0.15% in the last 24 hours and up +0.00% over the past month.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
See More
Previous Close:
$6.59
Open:
$6.8
24h Volume:
102.46K
Relative Volume:
0.04
Market Cap:
$45.43M
Revenue:
$5.21M
Net Income/Loss:
$-26.35M
P/E Ratio:
-0.2057
EPS:
-32.0862
Net Cash Flow:
$-20.84M
1W Performance:
+13.21%
1M Performance:
+0.00%
6M Performance:
+1,003%
1Y Performance:
+2,107%
1-Day Range:
$6.56
$7.14
1-Week Range:
$5.83
$7.30
52-Week Range:
$0.129
$8.00
Plus Therapeutics Inc Stock (PSTV) Company Profile
Name
Plus Therapeutics Inc
Sector
Industry
Phone
737.255.7194
Address
4200 MARATHON BLVD., AUSTIN, TX
Compare PSTV vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
6.60 | 45.36M | 5.21M | -26.35M | -20.84M | -32.09 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-03-26 | Initiated | Lake Street | Buy |
| Sep-03-25 | Upgrade | D. Boral Capital | Hold → Buy |
| Mar-17-25 | Initiated | D. Boral Capital | Buy |
| Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
| Oct-16-20 | Initiated | Maxim Group | Buy |
Plus Therapeutics Inc Stock (PSTV) Latest News
Plus Therapeutics (PSTV) Highlights Economic Benefits of Early D - GuruFocus
Plus Therapeutics Presents Health Economics Study Demonstrating Substantial Healthcare Cost Reduction with CNSide Diagnostic Platform - marketscreener.com
Plus Therapeutics study shows CNSide may cut LM costs by 40% - Investing.com
Plus Therapeutics Showcases CNSide's Impact on Early Diagnosis and Cost Reduction at ISPOR Annual Meeting - Quiver Quantitative
Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases - Yahoo Finance
Plus Therapeutics secures FDA orphan drug status for pediatric glioma treatment - MSN
PSTV Should I Buy - Intellectia AI
PSTV Technical Analysis | Trend, Signals & Chart Patterns | PLUS THERAPEUTICS INC (NASDAQ:PSTV) - ChartMill
Maxim Group Maintains Plus Therapeutics(PSTV.US) With Buy Rating, Maintains Target Price $12 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
PSTV Stock Price, Quote & Chart | PLUS THERAPEUTICS INC (NASDAQ:PSTV) - ChartMill
Total equity of Plus Therapeutics, Inc. – DUS:XMP1 - TradingView
Net current asset value per share of Plus Therapeutics, Inc. – DUS:XMP1 - TradingView
Total common shares outstanding of Plus Therapeutics, Inc. – DUS:XMP1 - TradingView
Total debt of Plus Therapeutics, Inc. – DUS:XMP1 - TradingView
Net margin % of Plus Therapeutics, Inc. – DUS:XMP1 - TradingView
Plus Therapeutics Stockholders Back Directors and Incentive Plan - TipRanks
Number of shareholders of Plus Therapeutics, Inc. – DUS:XMP1 - TradingView
Plus Therapeutics (PSTV) Forms Strategic Alliance with Ephemeral Technologies - GuruFocus
PLUS THERAPEUTICS, Inc.Common Stock (NQ: PSTV - The Chronicle-Journal
Plus Therapeutics partners with Ephemeral on AI platform By Investing.com - Investing.com South Africa
Plus Therapeutics, Inc. Cash Flow – DUS:XMP1 - TradingView
Plus Therapeutics partners with Ephemeral on AI platform - Investing.com
Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology - The Manila Times
Plus Therapeutics, Inc. Statistics – DUS:XMP1 - TradingView
AI team-up targets faster CNS cancer treatments at Plus Therapeutics - Stock Titan
Plus Therapeutics, Inc. Earnings and Revenue – DUS:XMP1 - TradingView
Plus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director ANDREWS RONALD ASBURYmoomoo - Moomoo
Plus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Hawkins Richard J - Moomoo
Equity grants for PLUS THERAPEUTICS (PSTV) director An van Es-Johansson - Stock Titan
Plus Therapeutics (PSTV) director receives new option and RSU awards - Stock Titan
Director at Plus Therapeutics (PSTV) receives new equity awards - Stock Titan
Plus Therapeutics (PSTV) director receives new option and RSU grants - Stock Titan
PLUS THERAPEUTICS (PSTV) director awarded new stock options and RSUs - Stock Titan
PLUS Therapeutics (PSTV) CFO receives new stock options and RSU grants - Stock Titan
Plus Therapeutics (PSTV) CEO receives new stock options and 23,834 RSUs - Stock Titan
Headline News about PLUS THERAPEUTICS, Inc.Common Stock - The Chronicle-Journal
Plus Therapeutics reports Q1 loss, raises $15M in offering - Investing.com India
Plus Therapeutics Q1 Loss Narrows, Revenue Declines - Moomoo
Plus Therapeutics (PSTV) Reports Q1 Revenue Exceeding Expectatio - GuruFocus
What Do Plus Therapeutics' Latest Financials Tell Us - Kavout
Plus Therapeutics shareholders approve board elections and key proposals at annual meeting - Investing.com Australia
Plus Therapeutics shareholders approve board elections and key proposals at annual meeting By Investing.com - Investing.com South Africa
Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Plus Therapeutics reports Q1 loss, raises $15M in offering By Investing.com - Investing.com South Africa
Plus Therapeutics (PSTV) investors approve directors, pay and 2020 stock plan changes - Stock Titan
PSTV: Net loss narrowed, cash declined, and future funding remains critical amid clinical and commercial progress - TradingView
Plus Therapeutics (PSTV) Q1 2026 loss highlights cash burn and going concern risk - Stock Titan
Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout - The Manila Times
Plus: Q1 Earnings Snapshot - marketscreener.com
Plus Therapeutics Inc Stock (PSTV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Plus Therapeutics Inc Stock (PSTV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| HEDRICK MARC H | Chief Executive Officer |
Apr 01 '26 |
Option Exercise |
0.00 |
159,681 |
0 |
499,468 |
| HEDRICK MARC H | Chief Executive Officer |
Jan 01 '26 |
Option Exercise |
0.00 |
159,681 |
0 |
339,787 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Jan 01 '26 |
Option Exercise |
0.00 |
38,323 |
0 |
106,461 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Nov 04 '25 |
Buy |
0.51 |
20,000 |
10,200 |
68,138 |
| HEDRICK MARC H | Chief Executive Officer |
Oct 01 '25 |
Option Exercise |
0.00 |
159,681 |
0 |
180,106 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Oct 01 '25 |
Option Exercise |
0.00 |
38,323 |
0 |
48,138 |
| Lenk Robert P | Director |
Aug 22 '25 |
Buy |
0.49 |
110,000 |
53,779 |
139,327 |
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):